Table V:

Utilization of the Sodhi and Benet (5) Methodology to Discriminate Clearance from Bioavailability Changes for Orally Dosed Apixaban (Victim) and Rifampin (Perpetrator) from the study of Vakkalagadda et al. (25)

Victim	Perpetrator	$\frac{{\mathit{A}\mathit{U}\mathit{C}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{A}\mathit{U}\mathit{C}}^{\mathit{C}\mathit{o}\mathit{n}\mathit{t}\mathit{r}\mathit{o}\mathit{l}}}$	$\frac{{{\mathit{V}}_{\mathit{s}\mathit{s}}/\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{{\mathit{V}}_{\mathit{s}\mathit{s}}/\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}\mathit{t}\mathit{r}\mathit{o}\mathit{l}}}$	$\frac{{{\mathit{V}}_{\mathit{s}\mathit{s}}}^{\mathit{D}\mathit{D}\mathit{I}}}{{{\mathit{V}}_{\mathit{s}\mathit{s}}}^{\mathit{C}\mathit{o}\mathit{n}\mathit{t}\mathit{r}\mathit{o}\mathit{l}}}$	$\frac{{\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}\mathit{t}\mathit{r}\mathit{o}\mathit{l}}}$	$\frac{{\mathit{C}\mathit{L}/\mathit{F}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{C}\mathit{L}/\mathit{F}}^{\mathit{C}\mathit{o}\mathit{n}\mathit{t}\mathit{r}\mathit{o}\mathit{l}}}$	$\frac{{\mathit{C}\mathit{L}}^{\mathit{D}\mathit{D}\mathit{I}}}{{\mathit{C}\mathit{L}}^{\mathit{C}\mathit{o}\mathit{n}\mathit{t}\mathit{r}\mathit{o}\mathit{l}}}$	Reference
Apixaban (IV) (Single Dose)	Rifampin (Multiple Dose)	Observed: 0.61	–	Observed: 0.87	Observed: 0.76	–	Observed: 1.64	(25)
Apixaban (Oral) (Single Dose)	Rifampin (Multiple Dose)	Observed: 0.48	Observed: 1.42a	Assumed: 1	Estimated: 0.70	Observed: 2.14	Estimated: 1.50	(25)

Pharmacokinetic values reported in the table are based on published average values, unless otherwise noted

Abbreviations: AUC, area under the curve; CL, clearance; CL/F, apparent clearance; DDI, drug-drug interaction; F, bioavailability; V_ss, volume of distribution at steady state; V_ss/F, apparent volume of distribution at steady state

^aRatios are calculated by digitization of published average plasma concentration-time profiles and performing non-compartmental and/or compartmental analysis